Effect In The Near Future Of Paclitaxel Combined With Carboplatin In Treatment Of Advanced Epithelial Ovarian Cancer

Ovarian cancer is one of three common types of gynecologic malignant tumor. Making the diagnosis in the early time is rare.It's often belong to III and IV phase when final diagnosis is made.The fatality rate of ovarian cancer is more than that's the sum of cervical carcinoma and carcinoma of endometrium.Because advanced epithelial ovarian cancer is 85%～90% of ovarian malignant tumor,it's therapeutic efficacy affects the evaluation to ovarian cancer's treatment on the maximum level.So far,the project of ovarian cancer's treatment mostly depends on the surgeon, assisted by chemical therapy and radioactive therapy. The epithelial ovarian cancer is the most sensitive to chemical therapy . In clinical treatment the platinum combined with other drugs is applied. However, because of diversity in biologic racteristics and specific property of easy to recur and transfer, recurrence and metastasis in ovarian cancer happens among 60% of the patients in some time after early therapy in time or advanced patients whose tumor tissues were resected in the large strange and accept the traditional chemical therapy. The first-line chemotherapy for patients with epithelial ovarian carcinomas is the combined-chemical therapy baced with platinum. Cisplatin and carboplatin have similar effects In the platinum category,but they have the different toxical-side effect. As cisplatin's neurotoxicity is overlap with Paclitaxel and Carboplatin's kidney toxicity,gastrointestinal and neurological toxicity reactions are slight than cisplatin, Therefore the majority of Gynecologic Oncology and the authoritative organization Center of the Gynecologic Oncology developed ovarian cancer treatment guidelines,so Carboplatin plus paclitaxel was recommended as the first-line chemotherapy for Epithelial Ovarian Cancer .To a certain extent, reduce the toxicity of chemotherapy and improve the quality of life of patients. In this paper,we to analyze and compare recent effect,CA₁₂₅ Index changes and toxical-side effect of TC project and PC project in the near future in the patients who accept chemical therapy after surgeon on the first time .Objective:To analyze and compare recent effect,CA₁₂₅ Index changes and toxical-side effect of TC project in the near future of PC project in the patients who accept surgeon and chemicatherapy after surgeon on the first time so as to evaluate the advantages and disadvantages.Methods:Choice in January 2004 to October 2007 in the Second Affiliated Hospital of Dalian Medical University, Jilin University and the second hospital treatment of patients with ovarian cancer screening in 46 patients with advanced (â…¢andâ…£) epithelial ovarian cancer patients were analyzed retrospectively. All patients received the ovarian cytoreductive surgery , The postoperative pathologic examination confirmed primary epithelial ovarian cancer. All cases after surgeon were divided into two groups, observation group and control group, accepted chemical therapy of TC and PC respectively. To analyze and compare effect,CA₁₂₅ Index changes and toxical-side effect according to the standard of WHO after six normal courses.Results:â‘´Recent effect:The paclitaxel and carboplatin chemotherapy group (TC programme) in the treatment of 20 patients in the total response rate (CR+PR) 85.0%; the total response rate (CR+PR) 57.69% in 26 patients of PC group.Throughχ² test, P<0.05.the effect of the two groups was significant difference.⑵Changes in the level of CA₁₂₅:The serum CA₁₂₅ average in two patients with preoperative all more than100U/ml,After No.3 chemotherapy, TC Group of 20 patients,16 patients (80%) with serum CA₁₂₅ levels dropped to below normal levels (35U/ml for the normal threshold),and only 13 cases (50%) patients with normal levels of serum CA₁₂₅ to below in the PC group of 26 patients,Throughχ² test, P <0.05. the effect of the two groups are significant difference.⑶Comparison of two toxicity side effects: TC Group toxicity in the blood system was higher than that of PC group, mainly as bone marrow suppression, TC group is significantly lower than PC group in gastrointestinal reactions,neurological toxicity and incidence of renal toxicity, Cardiovascular toxicity and the incidence of drug fever has no significant difference. In the process of using paclitaxel, in strictly accordance with the former anti-allergy medication before treatment, there are not a serious allergic reaction clinically.Conclusions:â‘´The project of paclitaxel combined with Carboplatin after surgeon has pretty better effect in the near future than that's the traditional Cyclophosphamide combined with Cisplatin chemical project.⑵After No. 3 chemotherapy treatment, decrease of the serum CA₁₂₅ in TC group was significantly greater than that in PC group.⑶The toxical-side effect of TC project obviously less than that's traditional PC project. So the patients'tolerance to chemical therapy and quality of life are improved.